Shidong Jia
CEO Predicine
Seminars
Thursday 5th February 2026
KRAS & Beyond: Integrated Liquid Biopsy & MRD Solutions for Global Oncology Drug Development
12:20 pm
- End-to-end liquid biopsy solutions supporting KRAS, ADC, Radioligand, and broad oncology drug development programs
- Personalized tumor-informed MRD solutions with or without baseline tissue, alongside tissue-naive methylation-based MRD approaches
- Harmonized tissue and liquid biopsy testing solutions supporting global clinical trials across the U.S. and China
